Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioeqivalence study of new procaterol hydrochloride hydrate dry powder inhaler and the approved dry powder inhaler in patients with asthma: A randomised, double-blind phase III study

Trial Profile

Bioeqivalence study of new procaterol hydrochloride hydrate dry powder inhaler and the approved dry powder inhaler in patients with asthma: A randomised, double-blind phase III study

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Procaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2017 New trial record
    • 01 Jan 2017 Primary endpoint of maximum FEV1 during the 480-minute measurement period has been met, according to results published in the Clinical Pharmacology in Drug Development.
    • 01 Jan 2017 Primary endpoint of area under the concentration-time curve (AUC) (FEV1)/h has been met, according to results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top